NASDAQ: MNKDMannkind Corp Stock
$4.91+0.18 (+3.81%)
Updated Apr 29, 2025
MNKD Price
$4.91
Fair Value Price
N/A
Market Cap
$1.49B
52 Week Low
$4.15
52 Week High
$7.63
P/E
49.1x
P/B
-18.91x
P/S
6.18x
PEG
1.06x
Dividend Yield
N/A
Revenue
$285.50M
Earnings
$27.59M
Gross Margin
73.2%
Operating Margin
23.99%
Profit Margin
9.7%
Debt to Equity
-6
Operating Cash Flow
$43M
Beta
1.1
Next Earnings
May 6, 2025
Ex-Dividend
N/A
Next Dividend
N/A
MNKD Overview
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine MNKD's potential to beat the market
BBuy
- Stocks with a Zen Rating of Buy (B) had an average return of +19.88% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
MNKD
Ranked#27 of 462
Ranked#27 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.96 | A | |
| $8.12 | A | |
| $24.28 | A |
Be the first to know about important MNKD news, forecast changes, insider trades & much more!
MNKD News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how MNKD scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MNKD ($4.91) is trading above its intrinsic value of $2.21, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
MNKD is poor value based on its earnings relative to its share price (49.1x), compared to the US market average (29.19x)
P/E vs Market Valuation
MNKD is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more MNKD due diligence checks available for Premium users.
Valuation
MNKD price to earnings (PE)
For valuing profitable companies with steady earnings
Company
49.1x
Industry
-158.75x
Market
29.19x
MNKD is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
MNKD is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
MNKD price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-18.91x
Industry
4.37x
MNKD price to earnings growth (PEG)
For valuing profitable companies with growth potential
MNKD is poor value relative... subscribe to Premium to read more.
PEG Value Valuation
MNKD's financial health
Profit margin
Revenue
$76.8M
Net Income
$7.4M
Profit Margin
9.7%
MNKD's Earnings (EBIT) of $68.50M... subscribe to Premium to read more.
Interest Coverage Financials
MNKD's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$393.8M
Liabilities
$472.7M
Debt to equity
-6
MNKD's short-term assets ($268.31M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MNKD's long-term liabilities ($390.82M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MNKD's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
MNKD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$22.6M
Investing
$48.2M
Financing
-$86.9M
MNKD's operating cash flow ($42.51M)... subscribe to Premium to read more.
Debt Coverage Financials
MNKD vs Biotech Stocks
Mannkind Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.